secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2021-10-28T23:59:59+00:00
Accession:  0001193125-21-310422
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q3 product rev $167M; Founder CEO to step down, Greenstreet to become CEO Jan 2022
--------------------------------------------------------------------------------

- Q3 2021 net product revenues $167M (ONPATTRO $120M, GIVLAARI $32M, OXLUMO $15M); GAAP net loss $204.5M ($1.72 loss per share).
- FY 2021 guidance reiterated: combined net product revenues $640M-$665M; GAAP R&D+SG&A $1.335B-$1.455B.
- Founding CEO John Maraganore to step down Dec 31, 2021; President/COO Yvonne Greenstreet appointed CEO effective Jan 1, 2022.
- Maraganore to consult through Mar 31, 2022 and remain on Scientific Advisory Board; Greenstreet also appointed to Board.
- Cash and investments $2.33B as of Sep 30, 2021, up from $1.87B at Dec 31, 2020 due to Blackstone payment and credit facility draw.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312521310422/0001193125-21-310422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312521310422/d240930d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-310422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer